Neuronascent

Neuronascent is a clinical-stage biotech pioneering a novel approach to treating neurodegenerative diseases by enhancing the brain's innate ability to generate new neurons. Its proprietary platform screens for small molecules that promote neurogenesis, neuronal migration, and survival, aiming to halt or reverse disease progression with oral therapies. The company has advanced its lead candidate, NNI-362, into clinical development for Alzheimer's disease and is exploring applications in Parkinson's disease and developmental delay. Led by founder and CEO Dr. Judith Kelleher-Andersson, Neuronascent represents a unique player in the regenerative neurology space, targeting a significant unmet medical need with a non-invasive therapeutic strategy.

Proprietary screening platform to discover orally available small molecules that enhance endogenous neurogenesis (neuron regeneration), promoting the proliferation, survival, migration, and functional integration of new neurons in the adult brain.

Neuronascent competes in the neurodegenerative disease space against large pharma (e.g., Biogen, Eli Lilly, Roche) developing antibody therapies and other modalities, and numerous biotechs targeting tau, inflammation, and other pathways. Its direct competitors are few, as most neuroregenerative approaches involve invasive cell or gene therapy. Its main competitive edge is the oral small-molecule approach to neuron regeneration.